Costanzo (Humanitas): ‘Deucravacitinib induces psoriasis healing in 60% of patients’

“Compared to injectable therapies, we finally have a small molecule that can be taken orally once a day and that induces healing of psoriatic plaques in more than 60% of patients, as long as they continue to take it”. This was stated by Antonio Costanzo, full professor of Dermatology and director of the Dermatology Unit at the IRCCS Istituto clinico Humanitas in Rozzano (Milan), during the press conference with which Bristol Myers Squibb announced the green light from Aifa to the reimbursement of deucravacitinib for the treatment of moderate to severe psoriasis.